Obsidian Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OBX Nasdaq 2836 obsidiantx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Obsidian Therapeutics, Inc.

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting - Oct 2nd, 2026 7:05 am
Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now? - Aug 12th, 2026 7:11 pm
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls - Aug 6th, 2026 7:48 am
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls - Aug 5th, 2026 7:40 am
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma - Aug 5th, 2026 5:05 am